Home Cart Sign in  
Chemical Structure| 30652-11-0 Chemical Structure| 30652-11-0

Structure of Deferiprone
CAS No.: 30652-11-0

Chemical Structure| 30652-11-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload. Target: Deferiprone is an orphan drug designed and developed primarily by academic initiatives for the treatment of iron overload in thalassaemia. Deferiprone has been used in several other iron or other metal imbalance conditions and has prospects of wider clinical applications. Deferiprone has high affinity for iron and interacts with almost all the iron pools at the molecular, cellular, tissue and organ levels. Doses of 50-120 mg/kg/day appear to be effective in bringing patients to negative iron balance. Deferiprone increases urinary iron excretion, which mainly depends on the iron load of patients and the dose of the drug.

Synonyms: CGP 37391; DN 18001AF; Ferriprox

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Michel Y. Fares ; Maha A. Hegazy ; Ghada M. El-Sayed ; Maha M. Abdelrahmanc ; Nada S. Abdelwahab ;

Abstract: This work implements a combined experimental approach of analytical quality-by-design (AQbD) and green analytical chemistry (GAC) to develop an HPLC method for simultaneous determination of the two thalassemia drugs, deferasirox (DFX) and deferiprone (DFP), in biological fluid for the first time. This integration was designed to maximize efficiency and minimize environmental impacts, as well as energy and solvent consumption. To accomplish this goal, an analytical quality-by-design approach was performed, beginning with quality risk assessment and scouting analysis, followed by Placket–Burman design screening for five chromatographic parameters. Critical method parameters were thoroughly recognized and then optimized by using a two levels-three factors custom experimental design to evaluate the optimum conditions that achieved the highest resolution with acceptable peak symmetry within the shortest run time. The desirability function was used to define the optimal chromatographic conditions, and the optimal separation was achieved using an XBridge® HPLC RP-C18 (4.6 × 250 mm, 5 μm) column with ethanol : acidic water at pH 3.0 adjusted by phosphoric acid in the ratio of (70 : 30, v/v) as the mobile phase at a flow rate of 1 mL min−1 with UV detection at 225 nm at a temperature of 25 °C. Linearity was obtained over the concentration range of 0.30–20.00 μg mL−1 and 0.20–20.00 μg mL−1 for DFX and DFP, respectively, using 20.00 μg mL−1 ibuprofen (IBF) as an internal standard. The established method's greenness profile was evaluated and measured using various assessment tools, and the developed method was green. For the validation of the developed method, FDA recommendations were followed, and all the results obtained met the acceptance criteria. The suggested method was successfully used to study the pharmacokinetic parameters of DFX and DFP in rat plasma. Due to the substantial increase in bioavailability of the two iron chelating drugs, the results from this study strongly recommend their co-administration.

Purchased from AmBeed: ;

Alternative Products

Product Details of Deferiprone

CAS No. :30652-11-0
Formula : C7H9NO2
M.W : 139.15
SMILES Code : O=C1C(O)=C(C)N(C)C=C1
Synonyms :
CGP 37391; DN 18001AF; Ferriprox
MDL No. :MFCD00134497
InChI Key :TZXKOCQBRNJULO-UHFFFAOYSA-N
Pubchem ID :2972

Safety of Deferiprone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02173951 Beta Thalassemia Major PHASE2|PHASE3 UNKNOWN 2025-07-15 Pediatric Hematology clinic, A... More >>in Shams University, Cairo, Egypt Less <<
NCT00529152 Iron Overload PHASE3 COMPLETED 2025-07-08 Abo El Reish Hospital, Cairo U... More >>niversity, Cairo, Egypt|Children Hospital, Ain Shams University, Cairo, Egypt|Cipto Mangunkusumo National Hospital, Jakarta, 10010, Indonesia|University of Malaya Medical Center, Kuala Lumpur, 50603, Malaysia Less <<
NCT02635841 Pantothenate Kinase-Associated... More >> Neurodegeneration Less << NO_LONGER_AVAILABLE - -
NCT02191657 HIV Infection PHASE1 COMPLETED 2025-04-10 PAREXEL International, Bloemfo... More >>ntein,, 9324, South Africa Less <<
NCT00907283 Neurodegenerative Disease|Iron... More >> Overload Less << PHASE2 UNKNOWN 2025-12-24 Neurological Pathology Departm... More >>ent, Brotzu Hospital, Cagliari, 09134, Italy|Centre of Microcitemia and Congenital Anemias, Galliera Hospital, Genoa, 16128, Italy|Clinic of Neurology, University of Genoa, Genoa, 16132, Italy Less <<
NCT02477631 Myelodysplastic Syndrome With ... More >>Low-grade Lesions|Iron Overload Due to Repeated Red Blood Cell Transfusions Less << PHASE2 COMPLETED 2025-06-18 Chim Sheba Medical Center, Tel... More >> Hashomer, 52621, Israel Less <<
NCT02164253 ALS (Amyotrophic Lateral Scler... More >>osis)|Iron Overload Less << PHASE2 COMPLETED 2025-12-16 H?pital Roger Salengro, CHRU d... More >>e Lille, Lille, 59000, France Less <<
NCT01770652 Renal Impairment PHASE4 COMPLETED 2025-08-13 H?pital Maisonneuve-Rosemont, ... More >>Montreal, Quebec, H1T2M4, Canada|Algorithme Pharma Inc., Mount-Royal, Quebec, H3P3P1, Canada Less <<
NCT02443545 Iron Overload|Sickle Cell Dise... More >>ase|Other Anemias Less << PHASE4 TERMINATED 2019-08-21 UCSF Benioff Children's Hospit... More >>al Oakland, Oakland, California, 94609, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Children's Hospital of Michigan, Detroit, Michigan, 48201, United States|The Children's Hospital of Philadephia, Philadelphia, Pennsylvania, 19104-4399, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Hospital for Sick Kids, Toronto, Ontario, Canada|Zagazig University, Alexandria, Egypt|Ain Shams University, Cairo, Egypt|Cairo University, Cairo, Egypt|Pediatric Hospital of Cairo University, Cairo, Egypt|Asser Central Hospital, Abha, Saudi Arabia|Barts and The London, London, United Kingdom|Evelina Children's Hospital, London, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.19mL

1.44mL

0.72mL

35.93mL

7.19mL

3.59mL

71.86mL

14.37mL

7.19mL

References

 

Historical Records

Categories